Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ClorRelief is an intranasal antihistamine spray developed by Dr. Ferrer BioPharma for the treatment of allergic rhinitis and nasal congestion. The product's active ingredient is chlorpheniramine maleate, a first-generation alkylamine antihistamine that functions as a potent antagonist of the histamine H1 receptor. By competitively inhibiting H1 receptors on effector cells, ClorRelief reduces the allergic inflammatory response, alleviating symptoms such as sneezing, rhinorrhea, and nasal pruritus. The formulation is part of Dr. Ferrer BioPharma's 'Clor' product line, which utilizes a proprietary intranasal delivery system intended to provide localized relief with potentially reduced systemic side effects compared to oral antihistamines. It is currently marketed as an approved over-the-counter (OTC) product for both adults and children.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ClorRelief.